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Rabi 1 in Dysplasia of Barrett's Epithelia
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Cellular Biology andAnatomy and Pathology, Medical College of Georgia, and the
Augusta Veterans Affairs Medical Center, Augusta, Georgia
Barrett's esophagus predisposes affectedpatients to the development ofesophageal adenocarcino-
ma. The development of adenocarcinoma proceeds along a progression through low- and high-
grade dysplasia. Surveillance ofBarrett's patients requires serial endoscopic investigations and
grading mucosal biopsies. Unfortunately, grading of biopsies by conventional hematoxylin and
eosin staining isfraught with significant interobserver variations. We havefound in both biopsy and
resection specimens that immunostainingfor the small GTP bindingprotein Rab]I is increased in
low-grade dysplastic cells. This staining is lost in high-grade dysplastic cells. These results suggest
that low-grade dysplastic cells undergo an apical trafficking blockade, which is released as cells
progress to the less differentiated phenotype of high-grade dysplasia and adenocarcinoma.
Examination ofthe SKGT-4 esophageal adenocarcinoma cell line demonstratedprominent mRNA
andprotein expressionfor Rabli. Rabli immunostaining waspresent in SKGT-4 cells as aperin-
uclear nidus ofpunctate staining along with a more diffuse punctate pattern. Thus, Rabll expres-
sion was present in a esophageal adenocarcinoma cells in culture. Markers ofvesicle trafficking
may be criticalfactorsfor grading ofmucosal dysplastic transitions leading to adenocarcinoma.
INTRODUCTION
Gastroesophageal reflux disease
(GERD) is now recognized as a prevalent
cause of upper gastrointestinal symptoms
[17, 29]. While novel proton pump
inhibitor medications and prokinetics
have provided significant therapeutic
interventions in the treatment of GERD,
the complications of reflux disease
remain ofconsiderable concern. In partic-
ular, Barrett's esophagus or columnar
metaplasia of the distal esophagus carries
a 30- to 40-fold increased risk ofdevelop-
ing esophageal adenocarcinoma [11, 16,
31, 39]. A strong relationship has been
established between specialized intesti-
nal-type Barrett's epithelium and adeno-
carcinoma [11, 12, 14, 26, 27, 31, 39, 41].
This association of Barrett's epithelium
with adenocarcinoma has led to the rec-
ommendations that patients with Barrett's
epithelium undergo a program of regular
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endoscopic surveillance [28, 37]. Central
to this process ofsurveillance is the histo-
logical grading of serial endoscopic biop-
sies. Inherent to this protocol is the con-
cept that adenocarcinoma develops
through a progression through increasing
grades of dysplasia [23, 32, 36]. When
high-grade dysplasia (essentially carcino-
ma in situ) is detected, early resection of
the distal esophagus is indicated, since
the incidence offrank adenocarcinoma in
the remaining esophagus is high [11, 23,
40].
While high-grade dysplasia and ade-
nocarcinoma are generally easily dis-
cerned histologically, much greater inter-
observer variation has been reported for
the grading of low-grade dysplasia [34].
These uncertainties make the surveillance
of Barrett's more problematic, and lead to
confusion in identifying patients who need
more frequent biopsies. More importantly
inconsistencies in grading likely lead to
more frequent than necassary biopsy sur-
veillance of patients with benign disease.
Thus, many investigators have sought to
identify more objective criteria to identify
those patients with the greatest risk of
developing cancer. Recent studies suggest
that mutations of the p53 tumor suppres-
sor gene, as detected by immunohisto-
chemistry or flow cytometry, may be pre-
dictive of progression to high-grade dys-
plasia and adenocarcinoma [2, 3, 5, 15, 18,
25, 38, 43]. Genetic instability as deter-
mined by aneuploid or increased
G2\tetraploid fractions in flow cytometric
analysis and cellular ultrastructural
changes have been implicated in the
development of adenocarcinoma [20-22,
32, 33]. Still, the reliable identification of
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Figure 1. Rabl1 immunostaining in low-grade dysplasia within Barrett's mucosa. A
five pm section of archival paraffin embedded tissue from an esophageal resection of a
patient with adenocarcinoma arising within Barrett's epithelium was stained with Rabl 1
monoclonal antibody (8H10 ascites, 1:300, for 2 hours at room temperature). Specific
staining was visualized with alkaline phosphatase conjugated goat-anti-mouse IgG sec-
ondary and Vector Red chromagen. Sections were lightly counterstained with Mayer's
hematoxylin. Non-dysplastic Barrett's epithelium (at left) showed no significant staining.
Low-grade dysplastic cells (L) showed a prominent perinuclear vacuolar staining for
Rabl 1. However, cells demonstrating high-grade dysplastic phenotypes (H) showed dimin-
ished or absent staining. Bar = 20 pm.Goldenring et al.: Rab11 in dysplasia ofBarrett's epithelia 115
low-grade dysplasia versus readings of
indeterminant or reactive changes remains
a problem for biopsy grading.
INCREASED RABI 1
IMMUNOSTAINING IS ASSOCIATED
WITH LOW-GRADE DYSPLASIA
The small GTP-binding protein, Rab
11, is a ubiquitous protein in non-polar-
ized and polarized cells which is associat-
ed with plasma membrane vesicle recy-
cling systems [42]. In epithelial cells,
Rabi 1 is associated with sub-apical vesi-
cles in a numberofcells including the gas-
tric fundic, ileal, and colonic epithelia as
well as the squamous epthelium of the
esophagus [8]. In the gastric parietal cell,
RabI 1, as well as its closely related mole-
cular cousin Rab25, are located on the
tubulovesicular system which is responsi-
ble for the regulated recycling ofthe H/K-
ATPase to the secretory canaliculus [4,9].
Since dysplasia in Barrett's epithelia
appeared to correlate with a loss of apical
secretory phenotype, we sought to investi-
gate whether dysplasia alterred the expres-
sion and distribution of RabI 1 [30]. We
first investigated the staining for RabI 1 in
esophageal adencarcinoma resection spec-
imens. These resections are especially
appropriate for this analysis since they
usually contain the full range of pheno-
types from non-dysplastic Barrett's
columnar epithelia through low and high-
grade dysplasia into frank adenocarcino-
ma. In these resection specimens, little
staining forRabI 1 was oberved in the spe-
cialized intestinal cells of Barrett's
mucosa. However, we observed strong
staining in low-grade dysplastic cells
(Figure 1). RabI 1 antibodies stained large
supranuclear vesicles in low-grade dys-
plastic cells (Figure 1). Interestingly,
Rabi 1 staining became more diffuse or
non-detectable in high-grade dysplastic
cells and frank adenocarcinoma. Similar
results were obtained when specimens
were stained for Rab25. In contrast with
RabI 1 staining, staining for p53 showed
significant increases in high-grade dyspla-
sia and frank adenocarcinoma. While our
data therefore suggest that elevated p53
expression (a reflection of p53 mutation)
is a late finding and are similar to three
previous studies [6, 13, 35], it shouldbe
noted that other investigators have report-
ed elevations in p53 in low-grade dyspla-
sia [15, 18, 19, 24, 43]. Whether these dif-
ferences reflect differences in staining
technique or variations in histological
grading of biopsies remains to be deter-
mined. Nevertheless, these results do indi-
cate that Rabll staining reflects the pres-
ence of low-grade dysplasia.
To identify better the association of
Rabl1 mmunoreactivity with low-grade
dysplasia, 60 endoscopic biopsies were
examined retrospectively for histological
grading and RabI 1 immunoreactivity [30].
Thirty of the cases had previously been
graded as no dysplasia while 30 had been
graded as low-grade dysplasia. Eighty-
four percent ofbiopsies graded as low-
grade dysplastic mucosae stained for
RabI 1 with characteristic preinuclear
immunoreactivity. Twenty-four percent of
non-dysplastic biopsy samples displayed
perinuclear staining. While the staining in
non-dysplastic cells was less intense than
that in low-grade dysplastic regions, defi-
nite punctate perinuclear immunoreactivi-
ty could be detected in histologically non-
dysplastic biopsies. Interestingly, the three
blinded coders disagreed on the histologi-
cal grading of 17% of the biopsies, while
they disagreed on the RabI 1 staining inter-
pretation of only one out of the 60 biop-
sies. Thus, Rabi 1 staining appears to be
less susceptible to interobserver interpreta-
tion. It is also impertant that 2 biopsies
that were graded as low-grade dysplasia
by all three graders did not display RabI 1
immunostaining. Our results therefore
suggest that Rabi 1 immunostaining may
provide a reliable indicator of low-grade
dysplasia.116 Goldenring et al.: Rabl 1 in dysplasia ofBarrett's epithelia
DISTRIBUTION OF RAB11 IN
LOW-GRADE DYSPLASIA:
IMPLICATIONS FORTRAFFICKING
The pattern ofRabI 1 immunostaining
in low-grade dysplastic cells was consider-
ably different from the subapical staining
pattern that we had observed in most
epithelial cells [8]. Haggitt and colleagues
[20] have previously noted significant
ultrastructural changes in low-grade dys-
plastic cells. Notably, using electron
microscopy, they identified the presence of
large perinuclear vacuoles in low grade
dysplastic cells. Importantly, high-grade
dysplastic cell and adenocarcinoma cells
appeared to lose this perinuclear vacuole
[20]. The electron microscopic description
of a perinuclear vacuole was similar to the
pattern which we observed forboth RabI 1
and Rab25 immunostaining. We therefore
sought to identify the compartment
involved in the formation of the perinu-
clear vacuole by staining with antibodies
against two proteins associated with the
trans-Golgi apparatus, the mannose-6-
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Figure 2. Rabl1 expression in SKGT-4 cells. SKGT-4 cells (a kind gift of Dr. A. Albino,
Memorial Sloan-Kettering Medical Center) were cultured in 20 percent fetal calf serum in
DMEM-F12 on tissue culture plastic for 14 days. Cells from two T75 flasks were used to
prepare either total RNA by standard RNAZOL extraction or protein following dissolution in
1.5 percent SDS. At left 10 pg of rabbit parietal cell total RNA (PC) and 20 pg of SKGT-4
total RNA were resolved on 1.2 percent agarose formaldehyde gels and transferred to
Magnagraph membrane. The northern blot was then probed under moderate stringency
(1X SSPE, 55 C) with full length rabbit Rabl 1 cDNA probe. Labeled bands were visualized
on a Phosphorimaging screen (Molecular Dynamics). The image demonstrates the pres-
ence of Rabl 1 mRNA in SKGT-4 cells. At right, 25 pg of rabbit parietal cell protein and 100
pg of SKGT-4 protein were resolved on 15 percent SDS-PAGE gels and transferred to
Immobilon-P membrane.The western blot was then probed with anti-Rabl 1 antibodies (1:1
dilution of monoclonal culture supernate with 5 percent non-fat dry milk in Tris-buffered
saline) overnight at room temperature (8). Specific labeling was visualized by incubation
with horseradish peroxidase-conjugated goat-anti-mouse-lgG and enhanced chemilumi-
nescence detection with Supersignal reagent (Pierce).These results demonstrate the pres-
ence of prominent amounts of Rabl 1 protein in SKGT-4 cells.Goldenring et al.: Rab1 1 in dysplasia ofBarrett's epithelia 117
phosphate receptor and y-adaptin, a com-
ponent of the AP-1 adapter complex. Both
mannose-6-phosphate receptor and y-
adaptin colocalized with RabI 1 in the per-
inucelar vacuoles associated with low-
grade dysplasia. Importantly, immunos-
taining with both ofthe Golgi markers was
also markedly increased in the perinuclear
vacuole compared with both non-dysplas-
tic and high-grade dysplastic cells. These
results suggested that the vacuolar com-
partment in low-grade dysplasia was like-
ly a swollen trans-Golgi compartment.
Thus, the observed increase in staining for
both Rab 1 and Rab25 as well as the
Golgi markers could result from an apical
secretory blockade. Alternatively, since
Rab 1l is associated with apical and plas-
ma membrane recycling systems [7, 10,
42], the expanded vacuole could represent
an expanded apical recycling system. Such
a blockade of either apical trafficking or
apical recycling might be expected for a
cell which is in the process of transition
from an apically secreting mucous cell to a
less differentiated dysplastic cell. The
decrease in staining with these markers in
high-grade dysplasia would then reflect of
release of blockade at the trans-Golgi or
recycling system level in a cell that is now
trafficking membrane in a less polar fash-
ion, reflective ofdysplasia.
RAB 1I EXPRESSION IN SKGT-4
ESOPHAGEAL
ADENOCARCINOMA CELLS
Our investigations in archival tissue
samples suggested that low-grade dys-
plastic cells within Barrett's epithelia
demonstrated a trafficking defect causing
an accumulation ofRabi 1 within a perin-
uclear vacuolar compartment, rather than
a frank increase in protein expression.
This suggested that the transition between
low and high-grade dysplasia released a
trafficking blockade, rather than decreas-
ing expression. Unfortunately it is diffi-
cult to address questions of Rabi 1 distri-
bution and expression in archival tissue
samples. Furthermore, few cell lines have
ever been developed from esophageal
adenocarcinomas. Albino and colleagues
developed the SKGT-4 cell line from an
esophageal adenocarcinoma arising from
a segment ofBarrett's esophagus [1]. The
cell line grows as islands ofcells with het-
erogeneous phenotypes ranging from
poorly to moderately differentiated. We
studied the expression of RabI 1 in
SKGT-4 cells grown on tissue culture
plastic to near confluence. Total mRNA
from SKGT-4 cells was probed under
moderate stringency with cDNA probes
for ,the human RabI 1 sequences. Figure 2
demonstrates that SKGT-4 cells express
prominent levels of mRNA for Rabl1.
SKGT-4 cells also expressed significant
amounts of Rab25 mRNA (data not
shown). In addition, SKGT-4 cells
demonstrated prominent amounts of
immunoreactive protein for Rab11
(Figure 2). These results demonstrate that
esophageal adenocarcinoma cells do
express Rabl1.
To investigate the localization of
Rabi 1 within SKGT-4 cells, we studied
the distribution of Rabi 1 using a mono-
clonal antibody which is specific for
Rabll [8]. We compared Rabli
immunoreactivity with that for the EGF
receptor which is overexpressed in
esophageal adenocarcinoma cells. In
islands of moderately differentiated cells,
prominent lateral membrane staining for
EGF receptor was observed (Figure 3). A
perinuclear nidus ofpunctate Rabi 1 stain-
ing was observed in most cells along with
a more diffuse punctate pattern throughout
the cytoplasm. This pattern of perinucelar
staining is typicalformostRabi1-express-
ing non-polarized cells [4, 10]. No promi-
nent perinuclear vacuolar staining was
observed. Thus, given that the SKGT-4
cell line likely is reflective ofat least high-
grade dysplastic cells, the expression pat-
tern forRab 11 supports thelackofa secre-
tory blockade in high-grade dysplastic
cells. It remains to be determined whether
the vacuolar staining in low-grade dys-
plastic cells is due to a defect in either118 Goldenring et al.: Rab1 1 in dysplasia ofBarrett's epithelia
Figure 3. Rabl1 immunostaining in SKGT-4 cells. SKGT-4 cells were cultured in 20%
fetal calf serum in DMEM-F12 on permeable supports (Transwell-clear) for 10 to 14 days.
Cells were fixed in 4% paraformaldehyde for 15 min at 4 C. For immunostaining, cells were
permeabilized with 0.3% Triton X-100/5% donkey serum in phosphate buffered saline for
30 min and then incubated simultaneously with monoclonal anti-Rabl 1 (1:100) and goat
anti-EGF receptor (EGFr; 1:100) for two hours at room temperature. Specific labeling was
visualized with incubation with Cy5-donkey anti-mouse IgG and Bodipy-rabbit anti-goat
IgG. Dual immunofluorescence labeling was observed on a Molecular Dynamics confocal
fluorescence microscope. Images represent maximum intensity projection reconstructions
of forty 0.29 pm optical sections. EGFr staining is observed primarily along the ruffled lat-
eral borders of the cells. Most cells demonstrated a central perinuclear nidus of Rabl 1
staining (e.g. arrowhead) as well as a more diffuse punctate staining pattern in the cyto-
plasm. Bar = 2 pm.
trans-Golgi to plasma membrane traffick-
ing or apical recycling.
THE FUTURE OF BARRETT'S
BIOPSY SURVEILLANCE.
While several previous reports have
highlighted the variability of histological
grading based on hematoxylin and eosin
staining, our results along with those of
others indicate that more functional
markers may provide a better method for
grading Barrett's biopsies. Thus, Rabll
immunostaining may provide a function-
al assay of the changes in trafficking that
are inherent to the changes involved in
the transition to low-grade dysplasia.
This functional aspect would also explain
why some increases in staining can be
observed in histologically non-dysplastic
cells. Similarly, staining for p53
immunoreactivity may provide a func-
tional assessment ofthe mutational status
of higher grade dysplastic cells.
Unfortunately, no large prospective study
has attempted to compare all of the vari-
ous markers that are available. Such a
comparison is needed and might reveal
important algorithms for assessing the
Barrett's mucosa with multiple stains. It
seems likely that such a study might be
able identify parameters for the large
group of patients who never show pro-
gression of their mucosa through dyspla-
sia. Increases in the certainty of biopsy
grading might therefore allow significant
curtailment in the frequency ofendoscop-
ic surveillance for many patients.
Acknowledgements: This work was sup-
ported by grants to JRG from awards from
NIH NIDDKD (DK48370 and DK43405)
anda Veterans Administration MeritAward
and an internal research grant from the
Department of Pathology, Medical College
of Georgia to JL.Goldenring et al.: Rab1 1 in dysplasia ofBarrett's epithelia 119
REFERENCES
1. Altorki, N., Schwartz, G., Blundell, M.,
Davis, B., Kelsen, D., and Albino, A.
Characterization of cell lines established
from human gastric-esophageal adenocar-
cinomas. Cance. 72: 649-657, 1993.
2. Blount, P.L., Galipeau, P.C., Sanchez, C.A.,
Neshat, K., Levine, D.S., Yin, J., Suzuki,
H., Abraham, J.M., Meltzer, S.J., and Reid,
B.J. 17p allelic losses in diploid cells of
patients with Barrett's esophagus who
develop aneuploidy. Cancer Res. 54:2292-
2295, 1994.
3. Blount, P.L., Ramel, S., Raskind, W.H.,
Haggitt, R.C., Sanchez, C.A., Dean, P.J.,
Rabinovitch, P.S., and Reid, B.J. 17p allel-
ic deletions and p53 protein overexpression
in Barrett's adenocarcinoma. Cancer Res.
51: 5482-5486, 1991.
4. Calhoun, B.C. and Goldenring, J.R. Two
Rab proteins, VAMP-2, and SCAMPs are
present on immunoisolated gastric
tubulovesicles. Biochem. J. 325:559-564,
1997.
5. Casson, A.G., Manolopoulos, B., Troster,
M., Kerkvliet, N., O'Malley, F., Inculet, R.,
Finley, R., and Roth, J.A. Clinical implica-
tions of p53 gene mutation in the progres-
sion of Barrett's epithelium to invasive
esophageal cancer. Am. J. Surg. 167:52-57,
1994.
6. Flejou, J-F., Potet, F., Muzeau, F., Le
Pelletier, F., Fekete, F, and Henin, D.
Overexpression of p53 protein in Barrett's
syndrome with malignant transformation.
J. Clin. Pathol. 46:330-333, 1993.
7. Goldenring, J.R., Bhartur, S., Navarre, F.,
Wang, X., and Casanova, J. Rabi 1 and
Rab25 localize to the apical recycling sys-
tem in MDCK cells. Mol. Biol. Cell.
8:408a, 1997.
8. Goldenring, J.R., Smith, J., Vaughan, H.D.,
Cameron, P., Hawkins, W., and Navarre, J.
Rabll is an apically located small GTP-
binding protein in epithelial tissues. Am. J.
Physiol. 270(33):G515-G525, 1996.
9. Goldenring, J.R., Soroka, C.J., Shen, K.R.,
Tang, T.H., Rodriguez, W., Vaughan, H.D.,
Stoch, S.A., and Modlin, I.M. Enrichment
of rabll, a small GTP-binding protein, in
gastric parietal cells. Am. J. Physiol. 267:
G187-G194, 1994.
10. Green, E.G., Ramm, E., Riley, N.M., Spiro,
D.J., Goldenring, J.R., and Wessling-
Resnick, M. RabI1 is associated with trans-
ferrin-containing recycling compartments
in K562 cells. Biochem. Biophys. Res.
Commun. 239:612-616, 1997.
11. Haggitt, R.C. Barrett's esophagus, dyspla-
sia, and adenocarcinoma. Hum. Pathol.
25:982-993, 1994.
12. Hameeteman, W., Tytgat, G.N.J.,
Houthoff, H.J., and Van Den Tweel, J.G.
Barrett's esophagus: devlopment ofdyspla-
sia and adenocarcinoma. Gastroenterology
96:1249-1256, 1989.
13. Hamelin, R., Flejou, J.F., Muzeau, F., Potet,
F., Laurent-Puig, P., Fekete, F., and
Thomas, G. TP53 gene mutations and p53
protein immunoreactivity in malignant and
premalignant Barrett's esophagus. Gastro-
enterology 107:1012-1018, 1994.
14. Hamilton, S.R., Smith, R.R.L., and
Cameron, J.L. Prevalence and characteris-
tics of Barrett esophagus in patients with
adenocarcinoma ofthe esophagus oresoph-
agogastric junction. Hum. Pathol. 19:942-
948, 1988.
15. Hardwick, R.H., Shepherd, N.A.,
Moorghen, M., Newcomb, P.V., and
Alderson, D. Adenocarcinoma arising in
Barrett's oesophagus: evidence for the par-
ticipation ofp53 dysfunction in the dyspla-
sia/carcinoma sequence. Gut 35:764-768,
1994.
16. Iftikhar, S.Y., James, P.D., Steele, R.J.C.,
Hardcastle, J.D., and Atkinson, M. Length
of Barrett's oesophagus: an important fac-
tor in the development of dysplasia and
adenocarcinoma. Gut 33:1155-1158, 1992.
17. Isolauri, J. and Laippala, P. Prevalence of
symptoms suggestive of gastro-esophageal
reflux disease in an adult population. Ann.
Med. 27:67-70, 1995.
18. Jones, D.R., Davidson, A.G., Summers,
C.L., Murray, G.F., and Quinlan, D.C.
Potential application of p53 as an interme-
diate biomarker in Barrett's esophagus.
Ann. Thorac. Surg. 57:598-603, 1994.
19. Krishnadath, K.K., Tilanus, H.W., and van
Blankenstein, M.Accumulation ofp53 pro-
tein in normal, dysplastic, and neoplastic
Barrett's oesophagus. J. Pathol. 175:175-
180, 1995.
20. Levine, D.S., Reid, B.J., Haggitt, R.C.,
Rubin, C.E., and Rabinovitch, P.S.
Correlation of ultrastructural alterations
with dysplasia and flow cytometric abnor-
malities in Barrett's epithelium. Gastro-
enterology. 96:355-367, 1989.
21. Levine, D.S., Rubin, C.E., Reid, B.J., and
Haggitt, R.C. Specialized metaplastic
columnar epithelium in Barrett's esopha-
gus: a comparative transmission electron
microscopic study. Lab. Invest. 60:418-
431, 1989.
22. Meltzer, S.J., Yin, J., Manin, B., Rhyu, M.-
G., Cottrell, J., Hudson, E., Redd, J.L.,
Krasna, M.J,Abraham, J.M., and Reid, B.J.
Microsatellite instability occurs freqently
and in both diploid and aneuploid cell pop-
ulations of Barrett's-associated esophageal120 Goldenring et al.: Rab1 1 in dysplasia ofBarrett's epithelia
adenocarcinomas. Cancer Res. 54:3379-
3382, 1994.
23. Miros, M., Kerlin, P., and Walker, N. Only
patients with dysplasia progress to adeno-
carcinoma in Barrett's oesophagus. Gut 32:
1441-1446, 1991.
24. Moskalluk, C.A., Heitmiller, R., Zahurak,
M., Schwab, D., Sidransky, D., and
Hamilton, S.R. p53 and p21WAF1/CIP1/
SDI1 gene products in Barrett's esophagus
and adenocarcinoma of the esophagus and
esophagogastric junction. Hum. Pathol.
27:1211-1220, 1996.
25. Neshat, K., Sanchez, C.A., Galipeau, P.C.,
Blount, P.L., Levine, D.S., Joslyn, G., and
Reid, B.J. p53 mutations in Barrett's adeno-
carcinoma and high-grade dysplasia.
Gastroenterology 106:1589-1595, 1994.
26. Nishimaki, T., Holscher, A.H., Schuler, M.,
Bollschweiler, E., Becker, K., and Siewert,
J.R. Histopathologic characteristics of
early adenocarcinoma in Barrett's esopha-
gus. Cancer 68:1731-1736, 1991.
27. Ovaska, J., Miettinen, M., and Kivilaakso,
E. Adenocarcinoma arising in Barrett's
esophagus. Dig. Dis. Sci. 34:1336-1339,
1989.
28. Provenzale, D., Kemp, J.A., Arora, S., and
Wong, J.B. A guide for surveillance of
patients with Barrett's esophagus. Am. J.
Gastroenterol. 89:670-680, 1994.
29. Raiha, I.J., Impivaara, O., Seppala, M., and
Sourander, L.B. Prevalence and character-
istics of symptomatic gastroesophageal
reflux disease in the elderly. J. Am. Geriat.
Soc. 40:1209-1211, 1992.
30. Ray, G.S., Lee, J.R., Nwokeji, K, Mills,
L.R., and Goldenring, J.R. Increased
immunoreactivity for RabI1, a small GTP-
binding protein, in low-grade dysplastic
Barrett's epithelia. Lab. Invest. 77:503-511,
1997.
31. Reid, B.J. Barrett's esophagus and
esophageal adenocarcinoma.
Gastroenterol. Clin. North Am. 20:817-
834, 1991.
32. Reid, B.J., Blount, P.L., Rubin, C.E.,
Levine, D.S., Haggitt, R.C., and
Rabinovitch, P.S. Flow-cytometric and his-
tological progression to malignancy in
Barrett's esophagus: Prospective endoscop-
ic surveillance of a cohort.
Gastroenterology. 102:1212-1219, 1992.
33. Reid, B.J., Haggitt, R.C., Rubin, C.E., and
Rabinovitch, P.S. Barrett's esophagus:
Correlation between flow cytometry and
histology in detection ofpatients at risk for
adenocarcinoma. Gastroenterology 93:1-
11, 1987.
34. Reid, B.J., Haggitt, R.C., Rubin, C.E.,
Roth, G., Surawicz, C.M., Van Belle, G.,
Lewin, K., Weinstein, W.M., Antonioli,
D.A., Goldman, H., MacDonald, W., and
Owen, D. Observer variation in the diagno-
sis of dysplasia in Barrett's esophagus.
Hum. Pathol. 19:166-178, 1988.
35. Rice, T.W., Goldblum, J.R., and Falk, G.W.
P53 immunoreactivity in Barrett's metapla-
sia, dysplasia and carcinoma. J. Thorac.
Cardiovasc. Surg. 108:1132-1137, 1994.
36. Riddell, R.H., Goldman, H., Ransohoff,
D.F., Appelmann, H.D., Fenoglio, C.M.,
Haggitt, R.C., Ahren, C., Correa, P.,
Hamilton, S.R., Morson, B.C., Sommers,
S.C., andYardley, J.H. Dysplasia in inflam-
matory bowel disease: standardized classi-
fication with provisional clinical applica-
tions. Hum. Pathol. 14:931-967, 1983.
37. Robertson, C.S., Mayberry, J.F.,
Nicholson, D.A., James, P.D., and
Atkinson, M. Value of endoscopic surveil-
lance in the detection of neoplastic change
in Barrett's oesophagus. Br. J. Surg.
75:760-763, 1988.
38. Sorsdahl, K., Casson, A.G., Troster, M.,
Meyel, D.V., Inculet, R., and Chamber, A.F.
p53 and ras gene espression in human
esophageal cancer and Barrett's epithelium:
A prospective study. Cancer Detect.
Prevent. 18:179-185, 1994.
39. Spechler, S.J. and Goyal, R.K. Barrett's
esophagus. New Engl. J. Med. 315:362-
371, 1986.
40. Starnes, V.A., Adkins, R.B., Ballinger, J.F.,
and Sawyers, J.L. Barrett's Esophagus: A
surgical entity. Arch. Surg. 119:563-567,
1984.
41. Thompson, J.J., Zinsser, K.R., and
Enterline, H.T. Barrett's metaplasia and
adenocarcinoma of the esophagus and gas-
troesophageal junction. Hum. Pathol.
14:42-61, 1983.
42. Ullrich, O., Reinsch, S., Urbe, S., Zerial,
M., and Parton. R.G. RabI 1 regulates recy-
cling through the pericentriolar recycling
endosome. J. Cell Biol. 135:913-924, 1996.
43. Younes, M., Lebovitz, R.M., Lechago,
R.M., and Lechago, J. p53 protein accumu-
lation in Barrett's metaplasia, dysplasia and
carcinoma: a follow-up study. Gastro-
enterology 105:1637-1642, 1993.